News Detail
Maryland, 7 Jan 2025: Following Viatris’ December announcement that a manufacturing plant in India had been written up by the FDA, a document published by the U.S. regulator reveals the details behind the company's manufacturing infractions.
In a warn......
View Details
Source : Fierce Pharma
Mylan
Viatris
India
U.S. FDA
FDA warning letter
FDA inspection
quality control
drug manufacturing
import alert
Facilities
Fierce Pharma Homepage
Manufacturing
Pharma
Related News
- FDA issues Draft Guidance on including Tissue Biopsies in Clinical Trials (08-01-2025)
- Punjab Police busts illegal pharma opioids network, arrests 4 with 2.10 lakh prohibited tablets (08-01-2025)
- Oxytocin being given to animals in the city's dairies, High Court expressed surprise (08-01-2025)
- Two Indian companies and Executive charged by US over importing ingredients for fentanyl (08-01-2025)
- Punjab Police raids Baddi pharma unit (08-01-2025)
- Three drug smugglers arrested with 5200 narcotic capsules in Abohar (07-01-2025)
- CSIR developed indigenous technology for paracetamol manufacturing (07-01-2025)
- Medical device sales hit Rs 8039.63 crore under PLI scheme (07-01-2025)
- Six new biomarkers could transform kidney injury monitoring and treatment (07-01-2025)
- IPC raises alarm on adverse reaction caused by Beta- blocker drugs (07-01-2025)